ID   WM793
AC   CVCL_8787
AS   CVCL_5414
SY   WM-793; WM 793; WML 793; WM793B; WM-793B; WM 793B; WM793b; WC00062
DR   BTO; BTO:0004612
DR   CLO; CLO_0009619
DR   EFO; EFO_0002873
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2806
DR   BioGRID_ORCS_Cell_line; 343
DR   BioSample; SAMN03471791
DR   BioSample; SAMN10987987
DR   cancercelllines; CVCL_8787
DR   Cell_Model_Passport; SIDM00973
DR   ChEMBL-Cells; CHEMBL4630605
DR   ChEMBL-Targets; CHEMBL4630705
DR   Coriell; WC00062
DR   Cosmic; 686397
DR   Cosmic; 886836
DR   Cosmic; 928693
DR   Cosmic; 972274
DR   Cosmic; 1155266
DR   Cosmic; 1155545
DR   Cosmic; 1155567
DR   Cosmic; 1238114
DR   Cosmic; 1303078
DR   Cosmic; 2159433
DR   Cosmic; 2163810
DR   Cosmic-CLP; 1299081
DR   DepMap; ACH-000827
DR   EGA; EGAS00001000978
DR   ESTDAB; ESTDAB-083
DR   GDSC; 1299081
DR   GEO; GSM109043
DR   GEO; GSM185202
DR   GEO; GSM185203
DR   GEO; GSM185204
DR   GEO; GSM185205
DR   GEO; GSM188235
DR   GEO; GSM188265
DR   GEO; GSM188324
DR   GEO; GSM887738
DR   GEO; GSM888833
DR   GEO; GSM952587
DR   GEO; GSM1670581
DR   IARC_TP53; 24995
DR   LiGeA; CCLE_074
DR   LINCS_LDP; LCL-1264
DR   PharmacoDB; WM793_1664_2019
DR   PRIDE; PXD004343
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_8787
DR   PubChem_Cell_line; CVCL_8787
DR   Wikidata; Q54994312
RX   PubMed=2068080;
RX   PubMed=2253310;
RX   PubMed=4053039;
RX   PubMed=8160777;
RX   PubMed=8342600;
RX   PubMed=11123321;
RX   PubMed=15592718;
RX   PubMed=16827748;
RX   PubMed=18632627;
RX   PubMed=22460905;
RX   PubMed=23851445;
RX   PubMed=24576830;
RX   PubMed=26589293;
RX   PubMed=27087056;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   https://web.archive.org/web/20141129125241/http://www.wistar.org:80/lab/meenhard-herlyn-dvm-dsc/page/melanoma-cell-lines-0
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: Wistar Institute melanoma cell line collection.
CC   Population: Caucasian.
CC   HLA typing: A*01:01,29:01; B*35:01,57:01; C*04:01:01,06:02; DPB1*04:01,04:01; DQB1*03:01:01,03:01:01; DRB1*11:03:01,11:03:01 (PubMed=15592718).
CC   HLA typing: A*01:01,29:01; B*35:02,57:01; C*04:01,06:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=16827748; PubMed=18632627; PubMed=23851445; PubMed=24576830; Cosmic-CLP; DepMap; Wistar).
CC   Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Lys22Gln (c.64A>C); ClinVar=VCV000485487; Zygosity=Homozygous (PubMed=23851445; Cosmic-CLP; DepMap; Wistar).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Trp274Ter (c.821G>A); ClinVar=VCV001762511; Zygosity=Heterozygous (PubMed=23851445; Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=2.43%; Native American=0.27%; East Asian, North=4.02%; East Asian, South=1.29%; South Asian=5.85%; European, North=24.77%; European, South=61.38% (PubMed=30894373).
CC   Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018. The major changes were: D18S51: 11,14->14,15.
CC   Discontinued: ATCC; CRL-2806; true.
CC   Discontinued: Coriell; WC00062; probable.
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
ST   Source(s): ATCC; Cosmic-CLP; ESTDAB; Genomics_Center_BCF_Technion; PubMed=27087056; Wistar
ST   Amelogenin: X (Wistar)
ST   Amelogenin: X,Y (ATCC; Cosmic-CLP; ESTDAB; Genomics_Center_BCF_Technion; PubMed=27087056)
ST   CSF1PO: 11
ST   D10S1248: 16
ST   D12S391: 18,24
ST   D13S317: 8,14
ST   D16S539: 12
ST   D18S51: 14,15
ST   D19S433: 13,15
ST   D1S1656: 12,17
ST   D21S11: 28,29
ST   D22S1045: 15,16
ST   D2S1338: 17,24
ST   D2S441: 11
ST   D3S1358: 14,16
ST   D5S818: 10,12
ST   D7S820: 10 (ESTDAB)
ST   D7S820: 10,12 (ATCC; Cosmic-CLP; Genomics_Center_BCF_Technion; PubMed=27087056; Wistar)
ST   D8S1179: 12,14
ST   DYS391: 10
ST   FGA: 20,21
ST   Penta D: 13
ST   Penta E: 5,12
ST   TH01: 6,8
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   37Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 30-01-24; Version: 38
//
RX   PubMed=2068080; DOI=10.1073/pnas.88.14.6028;
RA   Cornil I., Theodorescu D., Man S., Herlyn M., Jambrosic J.A.,
RA   Kerbel R.S.;
RT   "Fibroblast cell interactions with human melanoma cells affect tumor
RT   cell growth as a function of tumor progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:6028-6032(1991).
//
RX   PubMed=2253310; DOI=10.1007/BF00046337;
RA   Herlyn M.;
RT   "Human melanoma: development and progression.";
RL   Cancer Metastasis Rev. 9:101-112(1990).
//
RX   PubMed=4053039;
RA   Herlyn M., Thurin J., Balaban G.B., Bennicelli J.L., Herlyn D.,
RA   Elder D.E., Bondi E., Guerry D. IV, Nowell P.C., Clark W.H. Jr.,
RA   Koprowski H.;
RT   "Characteristics of cultured human melanocytes isolated from different
RT   stages of tumor progression.";
RL   Cancer Res. 45:5670-5676(1985).
//
RX   PubMed=8160777;
RA   Kobayashi H., Man S., MacDougall J.R., Graham C.H., Lu C.,
RA   Kerbel R.S.;
RT   "Variant sublines of early-stage human melanomas selected for
RT   tumorigenicity in nude mice express a multicytokine-resistant
RT   phenotype.";
RL   Am. J. Pathol. 144:776-786(1994).
//
RX   PubMed=8342600;
RA   Juhasz I., Albelda S.M., Elder D.E., Murphy G.F., Adachi K.,
RA   Herlyn D., Valyi-Nagy I.T., Herlyn M.;
RT   "Growth and invasion of human melanomas in human skin grafted to
RT   immunodeficient mice.";
RL   Am. J. Pathol. 143:528-537(1993).
//
RX   PubMed=11123321; DOI=10.4049/jimmunol.166.1.432;
RA   Li J., Pereira S., Van Belle P., Tsui P., Elder D.E., Speicher D.W.,
RA   Deen K., Linnenbach A., Somasundaram R., Swoboda R.K., Herlyn D.;
RT   "Isolation of the melanoma-associated antigen p23 using antibody phage
RT   display.";
RL   J. Immunol. 166:432-438(2001).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A.,
RA   Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R.,
RA   Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D.,
RA   Dummer R.;
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
//
RX   PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235;
RA   Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R.,
RA   Muthusamy V., King A.J., Flaherty K.T., Bosenberg M.W., Herlyn M.,
RA   Nathanson K.L.;
RT   "Identification of a novel subgroup of melanomas with
RT   KIT/cyclin-dependent kinase-4 overexpression.";
RL   Cancer Res. 68:5743-5752(2008).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625;
RA   Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C.-L.,
RA   Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A.,
RA   Chapman P.B., Yaeger R., Taylor B.S., Schultz N., Berger M.F.,
RA   Rosen N., Solit D.B.;
RT   "Loss of NF1 in cutaneous melanoma is associated with RAS activation
RT   and MEK dependence.";
RL   Cancer Res. 74:2340-2350(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27087056; DOI=10.1038/srep24569;
RA   Haridas P., McGovern J.A., Kashyap A.S., McElwain D.L.S., Simpson M.J.;
RT   "Standard melanoma-associated markers do not identify the MM127
RT   metastatic melanoma cell line.";
RL   Sci. Rep. 6:24569-24569(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//